Hassan W, Shrestha P, Sumida K, et al. Association of uric acid–lowering therapy with incident chronic kidney disease. *JAMA Netw Open*. 2022;5(6):e2215878. doi:10.1001/jamanetworkopen.2022.15878

**eTable 1.** Baseline Characteristics of Propensity Score–Matched Cohort  
**eTable 2.** Event Numbers and Event Rates in the Primary and Propensity Score Matched Cohorts  
**eFigure 1.** Schematic of Study Cohort  
**eFigure 2.** Propensity Score Distribution  
**eFigure 3.** Cumulative Incidence Function for Incident CKD in Patients Treated and Not Treated With Uric Acid–Lowering Therapy in the Propensity Score–Matched Cohort  
**eFigure 4.** Hazard of Incident eGFR Less Than 60 mL/min/1.73 m² and Incident Albuminuria Associated With Uric Acid Lowering Therapy in the Propensity Score–Matched Cohort

This supplemental material has been provided by the authors to give readers additional information about their work.
**Table 1. Baseline Characteristics of Propensity Score–Matched Cohort**

|                              | All $(n = 50,236)$ | Uric acid lowering therapy $(n = 25,118)$ | No uric acid lowering therapy $(n = 25,118)$ | Standardized difference |
|------------------------------|-------------------|------------------------------------------|---------------------------------------------|-------------------------|
| Age (years)                  | 56.9±11.1         | 56.8±10.5                                | 57.9±11.7                                  | 0.00573                 |
| Gender (male)                | 49,081 (98)       | 24,594 (98)                              | 24,487 (97)                                | 0.02843                 |
| Race                         |                   |                                          |                                            |                         |
| White                        | 36,482 (73)       | 18,196 (72)                              | 18,286 (73)                                |                         |
| African-American             | 11,770 (23)       | 5,971 (24)                               | 5,799 (23)                                 |                         |
| Other                        | 1,984 (4)         | 951 (3.8)                                | 1,033 (4)                                  |                         |
| Ethnicity (Hispanic)         | 2,920 (5.8)       | 1,442 (5.7)                              | 1,478 (5.9)                                | -0.00613                |
| Marital status               |                   |                                          |                                            |                         |
| Single                       | 4,597 (9.2)       | 2,147 (8.6)                              | 2,450 (9.8)                                | -0.00266                |
| Married                      | 27,393 (55)       | 13,879 (55)                              | 13,514 (54)                                |                         |
| Divorced                     | 14,602 (29)       | 7,333 (29)                               | 7,269 (29)                                 |                         |
| Widowed                      | 3,017 (6)         | 1,477 (5.9)                              | 1,540 (6.1)                                |                         |
| Unknown                      | 627 (1.3)         | 282 (1.1)                                | 345 (1.4)                                  |                         |
| Service connected            | 30,956 (62)       | 15,488 (62)                              | 15,468 (62)                                | -0.00164                |
| Insurance type               |                   |                                          |                                            | 0.01056                 |
| None                         | 22,203 (44)       | 11,059 (44)                              | 11,144 (44)                                |                         |
| Medicare                     | 17,328 (34)       | 8,852 (35)                               | 8,476 (34)                                 |                         |
| Other                        | 10,705 (21)       | 5,207 (21)                               | 5,498 (22)                                 |                         |
| RAAS inhibitors              | 35,000 (70)       | 17,570 (70)                              | 17,430 (69)                                | -0.01213                |
| Thiazide diuretics           | 27,037 (54)       | 13,598 (54)                              | 13,439 (54)                                | -0.01270                |
| Loop diuretics               | 13,136 (26)       | 6,523 (26)                               | 6,613 (26)                                 | 0.00815                 |
| Potassium sparing diuretics  | 6,124 (12)        | 3,066 (12)                               | 3,058 (12)                                 | -0.00097                |
| Other antihypertensives      | 33,761 (67)       | 16,908 (67)                              | 16,853 (67)                                | -0.00466                |
| NSAIDs                       | 40,868 (81)       | 20,546 (82)                              | 20,322 (81)                                | -0.02290                |
| Opioid                       | 39,304 (78)       | 19,691 (78)                              | 19,613 (78)                                | -0.00753                |
| SGLT2 inhibitors             | 790 (1.6)         | 402 (1.6)                                | 388 (1.5)                                  | -0.00448                |
| Proton pump inhibitors       | 29,793 (59)       | 14,926 (59)                              | 14,867 (59)                                | -0.00478                |
| Myocardial infarction        | 2,973 (5.9)       | 1,487 (5.9)                              | 1,486 (5.9)                                | -0.00017                |
| Congestive heart failure     | 3,731 (7.4)       | 1,831 (7.3)                              | 1,900 (7.6)                                | 0.01048                 |
| Condition                        | Group 1 | Group 2 | Group 3 | p-value |
|---------------------------------|---------|---------|---------|---------|
| Cerebrovascular disease         | 3,427 (6.8) | 1,677 (6.7) | 1,750 (7) | 0.01153 |
| Peripheral vascular disease     | 3,401 (6.8) | 1,699 (6.8) | 1,702 (6.8) | 0.00048 |
| Diabetes mellitus               | 13,713 (27) | 6,800 (27) | 6,913 (28) | 0.01010 |
| Charlson comorbidity index*     | 1 (2) | 1 (2) | 1 (2) | 0.04146 |
| Body mass index (kg/m²)         | 31.9±6.2 | 31.9±6 | 31.9±6.4 | -0.00676 |
| Systolic blood pressure (mmHg)  | 131.3±15.7 | 131.4±15.7 | 131.1±15.7 | -0.01511 |
| Diastolic blood pressure (mmHg) | 77.6±10.8 | 77.7±10.8 | 77.6±10.8 | -0.01192 |
| Estimated GFR (ml/min/1.73m²)   | 82.7±14.3 | 82.5±14.2 | 82.8±14.6 | 0.01744 |
| Serum uric acid (mg/dl)         | 7.6±1.5 | 7.7±1.5 | 7.6±1.4 | -0.08536 |

Results presented as number (percent) or means ± standard deviation.

RAAS, renin-angiotensin aldosterone system; NSAID, non-steroidal anti-inflammatory drug; SGLT2, sodium glucose co-transporter 2; GFR, glomerular filtration rate
**eTable 2.** Event Numbers and Event Rates in the Primary and Propensity Score Matched Cohorts

| Event                        | Primary cohort \((n = 269,651)\) | PS matched cohort \((n = 50,236)\) |
|------------------------------|----------------------------------|-----------------------------------|
|                              | Event numbers | Event rate (95%CI) | Event numbers | Event rate (95%CI) |
|                              | ULT=0 | ULT=1 | ULT=0 | ULT=1 | ULT=0 | ULT=1 | ULT=0 | ULT=1 |
| Incident eGFR<60             | 50,930 | 7,551 | 29.4 (29.15, 29.66) | 39.73 (38.83, 40.62) | 6,344 | 6,453 | 34.7 (33.85, 35.56) | 38.92 (37.99, 39.89) |
| Incident albuminuria         | 60,116 | 8,643 | 35.84 (35.55, 36.12) | 46.56 (45.58, 47.54) | 7,594 | 7,295 | 43.12 (42.16, 44.1)  | 45.01 (43.99, 46.06) |
| ESKD                         | 452    | 79    | 0.26 (0.23, 0.28)   | 0.4 (0.31, 0.49)  | 85    | 60    | 0.45 (0.37, 0.56)   | 0.36 (0.28, 0.46)  |

Data presented as numbers and events /1000 patient-years (95% confidence intervals)

ULT: uric acid lowering therapy; PS, propensity score
eFigure 1. Schematic of Study Cohort

TRI-CKD cohort entry: First eGFR ≥60 ml/min/1.73m² during fiscal year 2005-2006

Present cohort entry: First date of serum uric acid measurement following entry in parent cohort

Baseline date for treated: Date of first prescription for uric acid lowering therapy following first serum uric acid measurement

Baseline date for untreated: Randomly selected date matched with treated on duration from cohort entry

Study end point (incident CKD)

Last date of follow-up: September 30, 2019

At least one year without uric acid lowering therapy
≤180 days
eFigure 2. Propensity Score Distribution
**eFigure 3.** Cumulative Incidence Function for Incident CKD in Patients Treated and Not Treated With Uric Acid–Lowering Therapy in the Propensity Score–Matched Cohort
eFigure 4. Hazard of Incident eGFR Less Than 60 mL/min/1.73 m² and Incident Albuminuria Associated With Uric Acid Lowering Therapy in the Propensity Score–Matched Cohort